U-Home Group Holdings Ltd reports 1,640% Net Income growth in 2016 and 585% Revenue growth
26/03/2017 • About U-Home Group Holdings Ltd (
$2327) • By InTwits
U-Home Group Holdings Ltd reported FY2016 financial results today. Overall the company's long term financial model is characterised by the following facts: It operates with high leverage: Net Debt/EBITDA is 6.1x while industry average is -1.7x.
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.
U-Home Group Holdings Ltd ($2327) key annual financial indicators
| mln. HKD | 2012 | 2013 | 2014 | 2015 | 2016 | 2016/2015 |
|---|
P&L
|
|---|
| Revenue | 203.8 | 35.6 | 35.1 | 9.3 | 63.9 | 584.6% |
| Gross Profit | 35.3 | 7.9 | 5.5 | 5.5 | | -100.0% |
| SG&A | | | 10.1 | 7.6 | | -100.0% |
| EBITDA | 20.0 | -5.9 | -16.4 | 4.8 | | -100.0% |
| Net Income | 70.6 | 41.8 | 89.2 | 2.0 | 34.5 | 1,639.7% |
Balance Sheet
|
|---|
| Cash | 58.5 | 94.1 | 45.0 | 52.2 | | -100.0% |
| Short Term Debt | 261.1 | 181.2 | 100.0 | 100.0 | | -100.0% |
| Long Term Debt | 0.0 | 0.0 | 0.0 | 0.0 | | |
Cash flow
|
|---|
| Capex | 15.9 | 23.1 | 0.1 | 0.1 | | -100.0% |
Ratios
|
|---|
| Revenue growth | 16.2% | -82.5% | -1.6% | -73.4% | 584.6% | |
| EBITDA growth | -52.4% | -129.6% | 177.3% | -129.5% | | |
| Gross Margin | 17.3% | 22.2% | 15.6% | 58.7% | | -58.7% |
| EBITDA Margin | 9.8% | -16.6% | -46.7% | 51.7% | 0.0% | -51.7% |
| Net Income Margin | 34.7% | 117.1% | 254.3% | 21.2% | 53.9% | 32.7% |
| SG&A, % of revenue | | | 28.7% | 81.8% | | -81.8% |
| CAPEX, % of revenue | 7.8% | 64.9% | 0.2% | 0.6% | | -0.6% |
| ROIC | 2.3% | -0.8% | -3.3% | 2.0% | | -2.0% |
| ROE | 11.7% | 6.8% | 25.1% | 2.1% | | -2.1% |
| Net Debt/EBITDA | 10.1x | | | 9.9x | | -9.9x |
Revenue and profitability
The company's Revenue jumped on 585%.
Net Income marign jumped on 32.7 pp from 21.2% to 53.9% in FY2016.
Appendix 1: Peers in Pharmaceuticals
Below we provide U-Home Group Holdings Ltd benchmarking against other companies in Pharmaceuticals industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| China Health Group Inc ($8225) | | -48.0% | -60.1% | 244.1% | -1.2% |
| Wai Yuen Tong Medicine Holdings Ltd ($897) | | 45.9% | -10.5% | 105.6% | 40.9% |
| Oriental Unicorn Agricultural Group Ltd ($8120) | | -78.1% | 16.8% | 100.8% | 6.9% |
| China Traditional Chinese Medicine Co Ltd ($570) | | 35.2% | 90.0% | 40.0% | 76.1% |
| RM Group Holdings Ltd ($8185) | | 4.6% | -16.0% | 34.2% | -16.6% |
| |
|---|
| Median (41 companies) | 13.1% | 13.5% | 15.3% | 4.0% | 8.3% |
|---|
| U-Home Group Holdings Ltd ($2327) | | -82.5% | -1.6% | -73.4% | 584.6% |
Top companies by Gross margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Luye Pharma Group Ltd ($2186) | 83.5% | 83.6% | 81.0% | 81.4% | |
| Consun Pharmaceutical Group Ltd ($1681) | 75.7% | 79.1% | 78.3% | 80.7% | |
| Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049) | 82.0% | 81.5% | 80.9% | 79.9% | |
| RM Group Holdings Ltd ($8185) | 79.6% | 78.8% | 76.6% | 77.7% | 77.4% |
| Sino Biopharmaceutical Ltd ($1177) | 78.5% | 77.5% | 76.4% | 77.7% | 79.2% |
| |
|---|
| Median (40 companies) | 42.5% | 41.1% | 52.2% | 50.0% | 52.5% |
|---|
| U-Home Group Holdings Ltd ($2327) | 17.3% | 22.2% | 15.6% | 58.7% | |
Top companies by EBITDA margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | 193.8% | 205,840.0% | -15,344.8% | 49,650.0% | 26.0% |
| Sihuan Pharmaceutical Holdings Group Ltd ($460) | 38.8% | 65.4% | 70.9% | 93.3% | |
| Hua Han Bio-Pharmaceutical Holdings Ltd ($587) | 60.6% | 21.0% | 28.8% | 61.1% | |
| Beijing Tong Ren Tang Chinese Medicine Co Ltd ($8138) | 41.3% | 45.4% | 47.5% | 49.1% | 50.9% |
| Pak Fah Yeow International Ltd ($239) | 33.9% | 28.4% | 52.4% | 44.3% | |
| |
|---|
| Median (41 companies) | 20.7% | 20.6% | 21.4% | 19.0% | 11.9% |
|---|
| U-Home Group Holdings Ltd ($2327) | 9.8% | -16.6% | -46.7% | 51.7% | |
Top companies by CAPEX/Revenue, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Hao Wen Holdings Ltd ($8019) | 30.0% | 2.3% | 38.2% | 44.8% | |
| Hua Han Bio-Pharmaceutical Holdings Ltd ($587) | 0.9% | 1.4% | 7.6% | 40.5% | |
| Lee's Pharmaceutical Holdings Ltd ($950) | 18.6% | 20.9% | 7.1% | 26.1% | |
| Tianda Pharmaceuticals Ltd ($455) | 6.0% | 3.9% | 10.5% | 24.4% | 22.9% |
| Lijun International Pharmaceutical Holding Co Ltd ($2005) | 16.8% | 52.4% | 39.6% | 18.7% | |
| |
|---|
| Median (40 companies) | 8.3% | 8.1% | 7.6% | 4.6% | 4.0% |
|---|
| U-Home Group Holdings Ltd ($2327) | 7.8% | 64.9% | 0.2% | 0.6% | |
Top companies by ROIC, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Sino Biopharmaceutical Ltd ($1177) | 26.2% | 26.8% | 26.5% | 26.2% | 24.3% |
| Beijing Tong Ren Tang Chinese Medicine Co Ltd ($8138) | 25.3% | 27.5% | 23.8% | 25.9% | 25.1% |
| Sihuan Pharmaceutical Holdings Group Ltd ($460) | 13.7% | 18.3% | 22.0% | 25.4% | |
| Dawnrays Pharmaceutical Holdings Ltd ($2348) | 12.6% | 14.0% | 17.8% | 23.5% | |
| Lee's Pharmaceutical Holdings Ltd ($950) | 26.1% | 22.0% | 22.4% | 22.7% | |
| |
|---|
| Median (42 companies) | 12.3% | 9.3% | 11.1% | 10.9% | 6.4% |
|---|
| U-Home Group Holdings Ltd ($2327) | 2.3% | -0.8% | -3.3% | 2.0% | |
Top companies by Net Debt / EBITDA
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | 2.3x | 3.7x | | 22.2x | -5.1x |
| Lansen Pharmaceutical Holdings Ltd ($503) | 1.7x | 2.8x | 3.4x | 4.7x | |
| China Grand Pharmaceutical and Healthcare Holdings Ltd ($512) | 5.4x | 4.0x | 3.4x | 4.3x | |
| United Laboratories International Holdings Ltd/The ($3933) | 6.5x | 4.6x | 4.2x | 4.0x | |
| Shandong Xinhua Pharmaceutical Co Ltd ($719) | 3.5x | 3.4x | 2.8x | 3.4x | 2.7x |
| |
|---|
| Median (34 companies) | -0.4x | -0.4x | -0.6x | -0.6x | -1.3x |
|---|
| U-Home Group Holdings Ltd ($2327) | 10.1x | | | 9.9x | |
